Quantcast

Novartis’ eye care division Alcon buys US-based private mdical device company for $285M

Novartis’ eye care division Alcon has bought a privately-held US medical device company PowerVision, which focuses on focused on creating fluid-based intraocular lens implants, for $285 million at closing with additional payments based on specified regulatory and commercial milestones starting in 2023.

Read more

Novartis’s Alcon introduces new innovations in cataract surgery at ESCRS 2017 annual congress

Alcon, a division of Novartis, will introduce Clareon, the intraocular lens (IOL) with the most advanced optic material available in an automated, disposable, pre-loaded delivery system, at the XXXV European Society of Cataract & Refractive Surgeons (ESCRS) congress taking place October 7 – 11 in Lisbon, Portugal.

Read more

Alcon wins FDA’s approval for its intraocular lens for cataract surgery patients

Alcon, a division of Novartis, has received approval from the US Food and Drug Administration (FDA) for its AcrySof IQ ReSTOR +2.5 Multifocal Toric intraocular lens (IOL) with Activefocus optical design for patients undergoing cataract surgery who choose to address their astigmatism and presbyopia at the same time.

Read more

FDA OKs Alcon’s AcrySof IQ Aspheric IOL with the UltraSert Pre-loaded Delivery System for patients undergoing cataract surgery

Novartis’s Alcon has received US Food and Drug Administration (FDA) approval for its AcrySof IQ Aspheric IOL with the UltraSert Pre-loaded Delivery System for patients undergoing cataract surgery.

Read more